Orchestra BioMed (OBIO) vs. Its Rivals Head to Head Review

Orchestra BioMed (NASDAQ:OBIO) is one of 232 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Orchestra BioMed to similar companies based on the strength of its dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Profitability

This table compares Orchestra BioMed and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-1,779.71%	-58.32%	-41.47%
Orchestra BioMed Competitors	-742.74%	-148.05%	-29.47%

Valuation & Earnings

This table compares Orchestra BioMed and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	-$49.12 million	-2.96
Orchestra BioMed Competitors	$1.03 billion	$3.82 million	-7.41

Orchestra BioMed’s rivals have higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings for Orchestra BioMed and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	2	0	3.00
Orchestra BioMed Competitors	1573	4272	8277	222	2.50

Orchestra BioMed presently has a consensus target price of $17.00, suggesting a potential upside of 282.88%. As a group, “Surgical & medical instruments” companies have a potential upside of 29.93%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, research analysts plainly believe Orchestra BioMed is more favorable than its rivals.

Insider & Institutional Ownership

53.6% of Orchestra BioMed shares are held by institutional investors. Comparatively, 47.6% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.5% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Orchestra BioMed has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Orchestra BioMed’s rivals have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.

Summary

Orchestra BioMed rivals beat Orchestra BioMed on 7 of the 12 factors compared.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.